Fund shareholders of MOLECULIN BIOTECH INC
ISIN US60855D4088 · United States · LEI 549300IB1TLJZCHEO353
- Fund shareholders
- 6
- Of which ETFs
- 0 6 other funds
- Value held
- ≈ 228K $ 163.8K $ · 54.6K €
- Share of capital
- 0.3 % of 19.5M shares on Aug 6, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 28,274 | 78.9K $ | 0.00 % | 0.15 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 21,901 | 61.1K $ | 0.00 % | 0.11 % | as of May 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 4,484 | 12.5K $ | 0.02 % | as of May 31, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 3,142 | 8.8K $ | 0.02 % | as of May 31, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 915 | 2.6K $ | 0.00 % | as of May 31, 2026 ↗ | |
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 54.6K € | 0.29 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 0.29 % | as of Dec 31, 2025 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 5 | +1 | 58,716 | +97.7 % |
| 2026Q2 | 4 | +3 | 29,693 | +214.3 % |
| 2026Q1 | 1 | 9,448 |
Institutional managers
17 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 75,021 | 171.8K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 32,329 | 74K $ | as of Mar 31, 2026 |
| HRT FINANCIAL LP | 13,739 | 31 $ | as of Mar 31, 2026 |
| Rockefeller Capital Management L.P. | 4,421 | 10.1K $ | as of Mar 31, 2026 |
| UBS Group AG | 3,409 | 7.8K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 1,835 | 4.2K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 491 | 1.1K $ | as of Mar 31, 2026 |
| EFG International AG | 434 | 994 $ | as of Mar 31, 2026 |
| Pinnacle Wealth Planning Services, Inc. | 281 | 643 $ | as of Mar 31, 2026 |
| NFSG Corp | 114 | 261 $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 43 | 98 $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 36 | 83 $ | as of Mar 31, 2026 |
| FMR LLC | 3 | 7 $ | as of Mar 31, 2026 |
| DANSKE BANK A/S | 2 | 5 $ | as of Mar 31, 2026 |
| Caitong International Asset Management Co., Ltd | 2 | 5 $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 1 | 2 $ | as of Mar 31, 2026 |
| CVA Family Office, LLC | 1 | 2 $ | as of Mar 31, 2026 |
Declared shareholders of MOLECULIN BIOTECH INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| CVI Investments, Inc. and 1 other | 9.90 % | 1,863,377 | as of Jul 31, 2026 · SCHEDULE 13G |
| KLEMP WALTER V and 1 other | 9.90 % | 2,070,761 | as of Aug 19, 2026 · SCHEDULE 13D |
| Foster Jonathan P. | 6.30 % | 1,288,207 | as of Aug 19, 2026 · SCHEDULE 13D |
| Mitchell P. Kopin and 2 others | 4.99 % | 973,927 | as of Jul 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of MOLECULIN BIOTECH INC". https://titelia.com/en/stocks/moleculin-biotech-inc-US60855D4088